Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency.
about
Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccinePossible future monoclonal antibody (mAb)-based therapy against arbovirus infectionsExposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacyChikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoesChikungunya vaccines in developmentA potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesisLessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteinsDevelopment of a highly protective combination monoclonal antibody therapy against Chikungunya virusAntigenic Variation of East/Central/South African and Asian Chikungunya Virus Genotypes in Neutralization by Immune SeraA neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from diseaseChikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies.Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein.Human-like antibodies neutralizing Western equine encephalitis virus.Characterization of chikungunya virus-like particles.CD8+ T cells control Ross River virus infection in musculoskeletal tissues of infected mice.Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge.Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants.Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activityLongitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine developmentGene profiling of Chikungunya virus arthritis in a mouse model reveals significant overlap with rheumatoid arthritis.Autoimmunity in 2011.Chikungunya virus: recent advances in epidemiology, host pathogen interaction and vaccine strategies.Use of human monoclonal antibodies to treat Chikungunya virus infection.Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus.Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus.Analysis of antibody response (IgM, IgG, IgG3) to Chikungunya virus using panel of peptides derived from envelope protein for serodiagnosis.Structural Studies of Chikungunya Virus-Like Particles Complexed with Human Antibodies: Neutralization and Cell-to-Cell Transmission.Enzyme-linked immunosorbent assay using recombinant envelope protein 2 antigen for diagnosis of Chikungunya virus
P2860
Q24276414-A167271D-5E4A-463D-9C7A-B7CFE6CB12CAQ24289014-FED07A61-FCB2-45BF-9F30-94D8B56AF636Q24701766-3D98B4CB-15B3-4074-A67C-CBA87F483EC4Q24701786-026D1DC3-3978-46B6-8519-43DFE1C0E5E4Q26700081-87773FC9-BEA5-42B7-85AE-515F1A912E1AQ26700129-57D8439D-82D3-42BD-9B3A-6C1A3E77C876Q27013018-5AC175C0-EC4B-471C-8D0F-FDFAAB3C80ABQ27335008-382B594F-CCCB-4129-9FF5-5892FB5C3F8DQ27468808-62A568FC-8CBF-4371-B1D1-5BD5C557E712Q28533408-9DCC5E65-18C3-4E29-8350-8FD6169743F9Q30235512-A0A57374-72D6-4D46-9AF7-5CF7EC91FDCEQ30516488-9431CCA7-B5BA-430B-B098-415E297B01F7Q33573599-676295D0-60F4-47D3-9E9F-F832242B0A60Q34268026-0112F381-2C0B-4BEB-8228-84BD5967D624Q34810471-D27A2554-6751-4ED2-9517-EBBEF6D47AE8Q35238179-1B800DDE-EB39-409C-A4C8-91D0F4507AADQ35586877-18E485EC-9DD1-42C3-B190-5F837E386D4AQ35850197-855E2F44-0AB9-4CA4-9A2E-ECAC54A93A3DQ36300209-AB9C926D-C0C6-4D03-B545-DB91380DE5E9Q36397446-238C7D37-D270-4474-A7E4-95A674CE23F5Q37331952-899D238E-9827-4923-A533-BC957360BF3BQ38021696-FAE861DA-09BD-4C9B-A58A-024C698107BDQ38666344-12FA7388-7BEF-4710-AF04-5EF7E7BEE46EQ39012242-184461EA-654E-4C00-8B3D-493D0864AC0AQ40077669-ABEDFB25-8783-4DE7-AB4F-4D71C978C01DQ40113025-51E4C0B8-55F8-4DA3-991B-9F956A2965F4Q40232847-C2C138B2-C6F2-46E8-AAB1-178DA44E4D1CQ40922578-F220AD0A-E7D0-41D3-8740-DFFE8FF8CD56Q56396145-7AC25254-A6D4-45F0-BD19-0BB38E6492D4
P2860
Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Chikungunya virus envelope-spe ...... broad neutralization potency.
@ast
Chikungunya virus envelope-spe ...... broad neutralization potency.
@en
type
label
Chikungunya virus envelope-spe ...... broad neutralization potency.
@ast
Chikungunya virus envelope-spe ...... broad neutralization potency.
@en
prefLabel
Chikungunya virus envelope-spe ...... broad neutralization potency.
@ast
Chikungunya virus envelope-spe ...... broad neutralization potency.
@en
P2093
P50
P356
P1476
Chikungunya virus envelope-spe ...... broad neutralization potency.
@en
P2093
Alessandra Nardin
Cheng-I Wang
Chia Yin Lee
Jean-Pierre Abastado
Lucile Warter
Raymond T P Lin
Rekha Thiagarajan
Sebastien Bertin-Maghit
P304
P356
10.4049/JIMMUNOL.1003139
P407
P5008
P577
2011-01-28T00:00:00Z